1-3 of 3
Michael R. Cooper
Close
Sort by
Journal Articles

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Clinical Trials & Observations
Daniel J. DeAngelo, Richard M. Stone, Mark L. Heaney, Stephen D. Nimer, Ronald L. Paquette, Rebecca B. Klisovic, Michael A. Caligiuri, Michael R. Cooper, Jean-Michel Lecerf, Michael D. Karol, Shihong Sheng, Nick Holford, Peter T. Curtin, Brian J. Druker, Michael C. Heinrich
Journal: Blood
Blood (2006) 108 (12): 3674–3681.
https://doi.org/10.1182/blood-2006-02-005702
Published: 2006
Journal Articles

Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation.

Daniel J. De Angelo, MD,PhD, Richard M. Stone, MD, Mark L. Heaney, MD,PhD, Stephen D. Nimer, MD, Ronald Paquette, MD, Rebecca Bruner-Klisovic, MD, Michael A. Caligiuri, MD, Michael R. Cooper, MD, Jean-Michel LeCerf, PhD, Ganesh Iyer, PhD, Michael C. Heinrich, MD, Brian J. Druker, MD
Journal: Blood
Blood (2004) 104 (11): 1792.
https://doi.org/10.1182/blood.V104.11.1792.1792
Published: 2004
Journal Articles

Oncogenic Tyrosine Kinases Regulate Proliferative and Survival Signals through Activation of Id1.

Ting-Lei Gu, M.D./Ph.D., Winnie F. Tam, Ph.D., Jing Chen, Ph.D., Benjamin H. Lee, M.D./Ph.D, Andrew Z. Wang, M.D., Michael R. Cooper, M.D., Stefano Monti, Ph.D., Todd Golub, M.D., Gary D. Gilliland, Ph.D./M.D.
Journal: Blood
Blood (2004) 104 (11): 417.
https://doi.org/10.1182/blood.V104.11.417.417
Published: 2004